Akron Biotechnology, LLC

Akron Biotechnology, LLC is engaged in the provision of cGMP-compliant ancillary materials and manufacturing services vital for cell and gene therapy development. They cater to a diverse clientele, ensuring high-quality products for advanced therapeutic applications. Founded in 2006 and headquartered in Boca Raton, US, Akron Biotechnology specializes in providing critical materials for the biotechnology sector. The company was involved in two significant deals, with the most recent one taking place on September 11, 2019.

The current leadership includes CEO Christopher Murphy and Claudia Zylberberg, who have experience in biotechnology and related sectors. Akron Biotechnology specializes in offering high-quality cGMP-compliant ancillary materials and manufacturing services crucial for the development and commercialization of cell and gene therapies. Their product lineup features liquid cytokines, viral transduction enhancers, non-viral transfection reagents, and compliant plasmid DNA. These products support a wide range of clients, including pre-clinical, clinical, and commercial gene therapy and vaccine firms across North America, Europe, and Asia.

Their proprietary Closed System Solutions (CSS) product line ensures optimal dosing and sterility, catering to various manufacturing platforms in cell therapy production. The revenue structure of Akron Biotechnology is not publicly disclosed. However, it is understood that the company generates revenue primarily through B2B transactions involving direct sales to biotechnology companies and partnerships with clinical organizations. Their business model often involves contractual agreements for manufacturing services, including the production of recombinant proteins and specialized media with long-term supply commitments.

Their flagship products, such as cytokines and plasmid DNA, play a crucial role in therapeutic applications, with pricing tailored to the specific needs of clients. Akron Biotechnology plans to introduce new products addressing cell and gene therapy requirements, although specific launch dates have yet to be announced. The company is also focusing on market expansion, targeting regions in Europe and Asia for growth by the end of 2025. The funding from the majority stake acquisition by Arcline Investment Management in September 2019 will support these initiatives, enhancing their manufacturing capabilities and broadening their product offerings.